Guido Ficarra

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

Maria Vittoria Dieci, Carmen Criscitiello, Aïcha Goubar et al. · Annals of Oncology · 2014 · 461 citations · Full text

Residual Disease, Breast Oncology, Medicine +9

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis

Maria Vittoria Dieci, Elena Barbieri, Federico Piacentini et al. · Annals of Oncology · 2012 · 189 citations · Full text

Breast Oncology, Tumor Heterogeneity, Receptor Status +11

Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management

Valentina Guarneri, Simona Giovannelli, Guido Ficarra et al. · The Oncologist · 2008 · 152 citations · Full text

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Maria Vittoria Dieci, Aleix Prat, Enrico Tagliafico et al. · Annals of Oncology · 2016 · 149 citations · Full text

Breast Oncology, Pam50 Subtypes, Medicine +10

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients

Valentina Guarneri, Maria Vittoria Dieci, Elena Barbieri et al. · Annals of Oncology · 2013 · 140 citations · Full text

Breast Oncology, Neoadjuvant Therapy, Medicine +8